Paclitaxel is an agent widely used in second-line chemotherapy for advanced gastric cancer. The aim of this trial is to evaluate the efficacy and safety of 3-weekly or weekly doses of nanoparticle albuminbound-paclitaxel compared with weekly doses of Cremophor-based paclitaxel in patients with unresectable or recurrent gastric cancer refractory to first-line chemotherapy comprising fluoropyrimidines. A total of 730 patients will be enrolled from 72 institutions. The primary endpoint is the overall survival, and the secondary endpoints are progression-free survival, time to treatment failure, overall response rate, disease control rate, quality of life (by using the EQ-5D system) and safety.
Introduction
Gastric cancer remains the second leading cause of cancer-related deaths worldwide (1) , and it is especially frequent in East Asia, including Japan (2) . Paclitaxel (PTX) is the most commonly used agent in second-line chemotherapy for advanced gastric cancer (AGC) in Japan (3, 4) .
In Japan, the standard first-line of treatment for unresectable or recurrent gastric cancer is systemic chemotherapy consisting of S-1 (oral fluoropyrimidine) plus cisplatin or S-1 alone. According to the SPIR-ITS (5) and JCOG9912 (6) trials, the combination of S-1 plus cisplatin is the most frequently prescribed chemotherapy regimen for gastric cancer. However, standard second-line chemotherapy is not well established. Several Phase III studies have shown a survival benefit with second-line chemotherapy when compared with best supportive care (BSC) (7) (8) (9) .
A previously conducted Phase III trial (WJOG4007) compared weekly doses of PTX and irinotecan in previously treated gastric cancer patients. In this trial, no benefit in the overall survival (OS) was demonstrated with irinotecan (experimental arm) compared with weekly doses of PTX (control arm). Furthermore, PTX resulted in a better survival benefit than irinotecan did. The authors concluded that both chemotherapies were reasonable second-line treatment options (10) .
PTX, a microtubule-stabilizing agent, is widely used to treat breast, lung, gastric and ovarian cancers. The Cremophor® (solvent polyethoxylated castor oil)-containing PTX formulation has been approved, and it is prescribed worldwide. However, premedication with steroids and antihistamines-and H2-receptor blockers is essential before the administration of Cremophor-based PTX to reduce allergic reaction, hypersensitivity and anaphylactic reactions in the clinical setting.
Nanoparticle albumin-bound-paclitaxel (nab-PTX) is a 130-nm nanoparticle albumin-bound PTX formulation that does not require Cremophor or anhydrous ethanol. Nab-PTX thus reduces the risk of hypersensitivity reactions and does not require steroidal or antihistamine premedication. Furthermore, because the nab-PTX formulation does not contain alcohol, it can be administered to patients with poor alcohol metabolism (11) , thereby preventing alcohol-induced hypersensitivity reactions. Therefore, nab-PTX can be administered in shorter period of time (30 min) and without the need for special intravenous (i.v.) tubing; as such, polyethylene-lined i.v. bags composed of polyvinyl chloride can be used for nab-PTX administration (12, 13) .
A Phase II trial investigating the efficacy of 3-weekly doses of nab-PTX for AGC, by using the response rate (RR) as the primary endpoint, indicated promising results with a RR of 27.8% (95% confidence interval: 16.5-41.6%). The clinical response observed with second-line nab-PTX treatment appears to be comparable to that obtained in prior PTX trials (14) , although no direct comparison of the data has been performed.
In response to the results of this Phase II trial, we designed an investigational-drug arm-based Phase III trial with the purpose of establishing whether there is evidence to support 3-weekly doses of nab-PTX. In addition, weekly nab-PTX was included as another investigational-drug arm; based on the WJOG4007 trial, we judged it was appropriate to use weekly doses of Cremophor-based PTX as a control arm.
Details of the ABSOLUTE Trial protocol

Purpose
This study was designed to evaluate and compare the efficacy and safety of 3-weekly nab-PTX, weekly nab-PTX, and weekly Cremophor-based PTX for the treatment of patients with unresectable or recurrent gastric cancer refractory to prior chemotherapy containing fluoropyrimidines.
Study setting
This trial is a multiinstitutional (72 institutions), prospective, openlabel, randomized Phase III trial commencing in January 2013 in Japan.
Endpoints
The primary endpoint is OS, and the secondary endpoints are progression-free survival, time to treatment failure, overall response rate, disease control rate, quality of life (using the EQ-5D system) and safety.
Eligibility criteria
Prior to enrollment in the study, patients must fulfill all the following inclusion and exclusion criteria. 
Inclusion criteria
Registration/randomization
After confirmation of the eligibility, registration is made via a fax to the nab-PTX Registration Center. Patients are randomized at the ABI-007 Registration Center by using a minimization method that balances the arms considering the use of docetaxel as prior chemotherapy (present vs. absent), presence of peritoneal metastases (present vs. absent) and ECOG performance status (PS; 0 vs. 1 vs. 2) patients. Entered patients will be assigned randomly in a ratio of 1:1:1 to the 3-weekly nab-PTX arm, weekly nab-PTX arm and weekly Cremophor-based PTX arm.
Treatment methods
The following treatment methods will be repeated until the withdrawal criteria are met. Dose modification will depend upon the toxicities. The investigators will evaluate toxicities in order to appropriately adjust further treatment doses; dose modification will depend on the clinical judgment of the investigators. Neutrophil and platelet counts will be given particularly close attention. Once the study drug dose has been reduced, reescalation will not be allowed.
(A-arm) 3-weekly doses of nab-PTX The precautions on dosage and administration for the C-arm are the same as the B-arm.
Follow-up
Patients are assessed according to the Common Terminology Criteria for Adverse Events version 4.03 to detect any adverse events that develop during the treatment protocol. Patients are assessed via a verbal interview, physical examination and blood tests until any of the criteria for withdrawal from the study are met. The blood tests include a complete blood cell count, measurement of liver and renal function and tumor marker evaluations (carcinoembryonic antigen and carbohydrate antigen 19-9). Testing and observation assessments are performed every week during the first cycle, and at every administration thereafter.
Data on the OS, progression-free survival and objective response rate and time to progression evaluated according to the RECIST version 1.1 criteria will be collected. Computed tomography and magnetic resonance imaging will be performed every 8 weeks for measurements and evaluation. The patient's quality of life will be assessed by using the EQ-5D system.
Study design and statistical method
This randomized trial was designed to demonstrate that 3-weekly doses of nab-PTX or weekly doses of nab-PTX are not inferior to weekly doses of Cremophor-based PTX in terms of the OS.
The median OS is assumed to be 10.0 months in both the A-arm and B-arm, and 9.0 months in the C-arm, which corresponds to a hazard ratio (HR) of 0.9 for both the comparison between the nab-PTX treatment arms (A-arm and B-arm) and the comparison with the conventional PTX arm (C-arm). Assuming that the median OS with nab-PTX is not less than that with weekly PTX by >30% of the difference between weekly PTX and BSC (7) (8) (9) , the upper non-inferiority margin is calculated to be 1.25 for the HR. The overall significance level is set at 0.05, and the primary analysis will be performed by using the Holm method for multiple comparisons. To test the hypotheses with an 80% power, a registration period of 18 months, and a minimum follow-up period of 12 months, 230 patients per arm or 690 patients in total are required for analysis. Considering the possibility that 5% of the enrolled patients will be excluded from the analysis, the number of patients to be enrolled is set at 730. Patients will be randomly assigned in a 1:1:1 ratio to the A-arm, B-arm or C-arm via a minimization method with docetaxel-containing first-line treatment, peritoneal metastasis, and ECOG PS as the allocation factors.
The primary analysis will aim to test the following two comparisons with respect to the OS: (i) Non-inferiority of 3-weekly nab-PTX to weekly PTX as a control (ii) Non-inferiority of weekly nab-PTX to weekly PTX as a control Using data from the full analysis set, the confidence interval for the HR of OS with the study treatment will be calculated for each comparison by using a Cox proportional hazard model with treatment and stratification factors as the covariates. If the upper limit of the 97.5% confidence interval is below the non-inferiority margin of 1.25 for a comparison with a lower P value of the two, it will be judged that the nab-PTX regimen of the first comparison has been demonstrated to be non-inferior to weekly PTX. If the nab-PTX regimen of the first comparison is demonstrated to be non-inferior to weekly PTX, a noninferiority test of another comparison will be performed by using the non-inferiority margin of 1.25 and a 95% confidence interval.
Interim analysis and monitoring
No interim analysis is planned. The Data and Safety Monitoring Committee are installed as independent reviewers.
Registration of the protocol
The study protocol was registered at the website of the JAPIC Clinical Trials Information, JapicCTI-132059, on 30 January 2013. Details are searchable at the following address: http://www.clinicaltrials.jp/ user/cteSearch.jsp.
